Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 26, 2018
Tools & Techniques

Deconstructing the rule of five

The last 20 years of drugs undermines the relevance of the rule of five
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

How Ascletis’ performance could affect up to 100 biotechs hoping to list on HKEX
BioCentury | Aug 3, 2018
Financial News

Ascletis ends first trading week on downturn

BioCentury | Aug 1, 2018
Financial News

Ascletis trades flat in Hong Kong debut

BioCentury | Jul 27, 2018
Finance

First out the gate

Antiviral play Ascletis comes out of the gate on HKEX at $2B valuation
BioCentury | Jul 20, 2018
Financial News

Ascletis sets terms for Hong Kong IPO

BioCentury | Jun 1, 2018
Clinical News

Gilead's Epclusa approved in China for HCV

BioCentury | May 30, 2018
Company News

Gilead's Epclusa approved in China for HCV

Items per page:
1 - 10 of 600